An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2012
At a glance
- Drugs Buprenorphine (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 16 Apr 2012 Status changed from not yet recruiting to withdrawn as reported by ClinicalTrials.gov.
- 16 Apr 2012 Actual initiation date (July 2012) added as reported by ClinicalTrials.gov.
- 16 Apr 2012 Planned End Date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.